Details

Autor(en) / Beteiligte

• Kharitonenkov, Alexei
• Shiyanova, Tatiyana L
• Koester, Anja
• Ford, Amy M
• Micanovic, Radmila
• Galbreath, Elizabeth J
• Sandusky, George E
• Hammond, Lisa J
• Moyers, Julie S
• Owens, Rebecca A
• Gromada, Jesper
• Brozinick, Joseph T
• Hawkins, Eric D
• Wroblewski, Victor J
• Li, De-Shan
• Mehrbod, Farrokh
• Jaskunas, S Richard
• Shanafelt, Armen B

Titel

FGF-21 as a novel metabolic regulator

Ist Teil von

• The Journal of clinical investigation, 2005-06, Vol.115 (6), p.1627-1635

Ort / Verlag

United States: American Society for Clinical Investigation

Erscheinungsjahr

2005

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.